Lexaria Bioscience highlights the rapid growth of the oral GLP-1 drug market, projected to expand from $5.1 billion in 2026 to $89 billion by 2034. This growth is fueled by patient preference for oral medications over injections and advancements in Lexaria's DehydraTECH technology, which improves oral drug absorption and reduces side effects. Industry leaders like Novo see oral GLP-1 drugs potentially capturing up to half of the market, signaling a major shift in diabetes and weight-loss treatments. Lexaria is strategically positioned to benefit from this transition with its patented delivery platform under evaluation by pharmaceutical partners.
Novo Nordisk A/S (NVO) holds a substantial market cap of $163.99 billion and offers a dividend yield of 4.79%, reflecting its strong position in the health sector. As of October 6, 2026, 20:12 WIB, the stock price is USD 37.40 with a slight 1-day decline of 0.37% on Pluang. The company’s enterprise value stands at $178.31 billion, and trading volume reached 18,044,587 shares, indicating active investor interest in this leader of the GLP-1 oral medication market transition.
